Defunct Company
Total Trials
9
As Lead Sponsor
7
As Collaborator
2
Total Enrollment
3,184
NCT02458066
Trial to Compare Effectiveness of 2 Insecticides in Preventing Malaria
Phase: N/A
Role: Lead Sponsor
Start: Feb 28, 2014
Completion: Oct 31, 2014
NCT02613520
Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants
Phase: Phase 1
Role: Collaborator
Start: Dec 31, 2015
Completion: Mar 31, 2017
NCT02688101
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
Start: Apr 11, 2016
Completion: Oct 26, 2017
NCT02870634
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Start: Nov 16, 2016
Completion: Jan 30, 2020
NCT03204929
Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
Start: Aug 14, 2017
Completion: Feb 29, 2020
NCT03136809
ALS Treatment Extension Study
Phase: Phase 1/2
Start: Jan 18, 2018
Completion: Dec 31, 2022
NCT03420053
Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults
Start: Feb 7, 2018
Completion: Aug 25, 2018
NCT04082832
CuATSM Compared With Placebo for Treatment of ALS/MND
Phase: Phase 2/3
Start: Sep 30, 2019
Completion: Dec 30, 2020
NCT04313166
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
Phase: Phase 2
Start: Mar 19, 2020
Completion: Feb 15, 2022